Kazia Therapeutics Limited
Kazia Therapeutics Limited
Your view on KZIA
Overview
What the company does, where it operates, and who runs it.
About Kazia Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Edwin Friend II,
- Headquarters
- Three International Towers, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John Edwin Friend II,
- Headquarters
- Three International Towers, Sydney, NSW, AU
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma.
It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Kazia Therapeutics Limited, and the rating behind it. KZIA last traded at $11.19; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Kazia Therapeutics Limited. Starting points for Kazia Therapeutics Limited: EPS -$7.14, beta 2.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Kazia Therapeutics Limited. Kazia Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Kazia Therapeutics Limited. Trailing twelve-month EPS for Kazia Therapeutics Limited stands at -$7.14. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Kazia Therapeutics Limited. Kazia Therapeutics Limited has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Kazia Therapeutics Limited valued side by side against its closest peers. Kazia Therapeutics Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Kazia Therapeutics Limited, and how their positions are changing. At a $18.1M market value, institutional positions materially move Kazia Therapeutics Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Kazia Therapeutics Limited executives and directors. Shares of Kazia Therapeutics Limited have traded between $2.86 and $30.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Kazia Therapeutics Limited. Kazia Therapeutics Limited is a $18.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Kazia Therapeutics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Kazia Therapeutics Limited. Coverage tracks Kazia Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.